Biogen Inc (BIIB)

BIIB (NASDAQ:Drugs) EQUITY
$264.62
pos +1.50
+0.57%
Today's Range: 262.63 - 265.40 | BIIB Avg Daily Volume: 1,759,900
Last Update: 05/05/16 - 3:59 PM EDT
Volume: 1,104,788
YTD Performance: -14.11%
Open: $263.80
Previous Close: $263.12
52 Week Range: $242.07 - $420.99
Oustanding Shares: 219,051,491
Market Cap: 59,956,583,602
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 10 10 10
Moderate Buy 2 2 2 2
Hold 6 8 8 8
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.79 1.88 1.88 1.88
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 17.89
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
17.89 16.80 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-3.71% -31.87% 20.23%
GROWTH 12 Mo 3 Yr CAGR
Revenue 10.80 0.90 0.25
Net Income 22.20 1.60 0.37
EPS 24.00 1.60 0.38
Earnings for BIIB:
EBITDA 4.28B
Revenue 9.42B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $4.67 $4.74 $18.96 $20.28
Number of Analysts 22 22 22 22
High Estimate $5.29 $5.33 $20.80 $22.70
Low Estimate $4.41 $4.49 $18.40 $19.13
Prior Year $4.22 $4.48 $17.01 $18.96
Growth Rate (Year over Year) 10.70% 5.92% 11.49% 6.91%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Bruce Kamich

 | Apr 26, 2016 | 11:40 AM EDT

BIIB could be headed above $300 over the intermediate term.

By

Bret Jensen

 | Apr 22, 2016 | 9:00 AM EDT

There are lots of winners in the first quarter.

bearishBiogen estimates, target cut at Leerink

Apr 22, 2016 | 7:25 AM EDT

Shares of BIIB now seen reaching $319, according to Leerink Partners. Estimates also reduced, as the MS franchise is facing pressure. Market Perform rating. 

By

David Katz

 | Apr 20, 2016 | 7:00 AM EDT

Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.

By

Jim Cramer

 | Apr 6, 2016 | 2:50 PM EDT

With Pfizer deal dead, Allergan is ready to go shopping.

By

Dick Arms

 | Apr 5, 2016 | 7:00 AM EDT

The lack of fear, by way of the VIX, speaks volumes about where the market is headed.

By

Carolyn Boroden

 | Apr 4, 2016 | 7:00 AM EDT

Let's also take a look at Biogen, a biotech I like.

By

Gary Morrow

 | Mar 31, 2016 | 3:00 PM EDT

The biotech company's shares remain range-bound, but a fresh rally appears to be brewing.

By

Dick Arms

 | Mar 24, 2016 | 7:00 AM EDT

At the very least, move those stop loss levels in very close on long positions.

By

Jim Cramer

 | Mar 22, 2016 | 6:17 AM EDT

The group rallied yesterday, but it's still not out of the woods.

$550 million to buy market on close.

breadth is weak and fear is rising in front NFP. we will add protection. BOUGHT SPY MAY 20...
Market has lost early but slight gains, and now sports small losses. Equities don't seem ...
Is to find Yale Liebowitz's photo (he was Pablo's best friend in first grade) in The Donal...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.